Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 6,172 Shares

Insmed Incorporated (NASDAQ:INSM - Get Free Report) insider Martina M.D. Flammer sold 6,172 shares of the firm's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the sale, the insider now directly owns 101,549 shares of the company's stock, valued at approximately $6,462,578.36. This trade represents a 5.73 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The stock was sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $0.47 during trading on Friday, reaching $65.25. The stock had a trading volume of 3,087,759 shares, compared to its average volume of 1,881,810. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $71.29 and a two-hundred day simple moving average of $72.44. The firm has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. Insmed's revenue was up 18.1% on a year-over-year basis. During the same period last year, the company posted ($1.10) earnings per share. As a group, analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Institutional Trading of Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Orion Portfolio Solutions LLC boosted its position in shares of Insmed by 48.5% in the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company's stock valued at $2,050,000 after acquiring an additional 9,170 shares during the period. Ally Bridge Group NY LLC boosted its holdings in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company's stock valued at $11,011,000 after purchasing an additional 21,833 shares during the period. Vestal Point Capital LP increased its holdings in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock worth $116,800,000 after purchasing an additional 850,000 shares during the period. TimesSquare Capital Management LLC acquired a new position in shares of Insmed during the third quarter valued at about $35,322,000. Finally, Jennison Associates LLC lifted its stake in shares of Insmed by 3.4% in the third quarter. Jennison Associates LLC now owns 769,253 shares of the biopharmaceutical company's stock valued at $56,155,000 after buying an additional 24,973 shares during the period.

Wall Street Analysts Forecast Growth

INSM has been the subject of a number of research analyst reports. Truist Financial reissued a "buy" rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. increased their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research report on Friday, November 22nd. HC Wainwright restated a "buy" rating and set a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Finally, Bank of America increased their price objective on Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.